1. Introduction {#sec1-antibiotics-09-00026}
===============

*Helicobacter pylori* infection is correlated to upper gastrointestinal diseases such as peptic ulcers, gastric mucosa associated lymphoid tissue lymphoma (MALT), and gastric cancer \[[@B1-antibiotics-09-00026]\]. Antibiotic resistance is an increasing problem for eradication therapies, the trending abuse of antibiotics is probably the cause of this issue. The selective pressure of the antibiotic intake causes modification in the genetic pattern of *H. pylori* that stays stable generation after generation \[[@B2-antibiotics-09-00026]\]. Clarithromycin is a key antibiotic in *H. pylori* eradication regimens, it is a macrolide and inhibits protein synthesis by binding to the 23S rRNA component of the 50S subunit of the ribosome. Clarithromycin resistance is due to several point mutations in 23S rRNA gene; A2143G, A2142G, and A2142C represent \> 90% of the observed mutations with confirmed clinical relevance \[[@B3-antibiotics-09-00026],[@B4-antibiotics-09-00026]\]. Metronidazole is also involved in the eradication of the bacterium. It is a 5-nitroimidazole activated by *H. pylori* nitroreductase enzyme. In particular, the inactivation of rdxA (encodes an oxygen-insensitive NADPH nitroreductase) and frxA (encodes a NADPH flavin oxidoreductase) genes is highly associated with metronidazole resistance in *H. pylori* \[[@B5-antibiotics-09-00026]\]. Levofloxacin, a fluoroquinolone used in rescue therapeutic regimens, interacts with type II topoisomerases preventing the unwinding of DNA and DNA replication. Mutation in GyrA or GyrB genes are linked to levofloxacin resistance in *H. pylori* \[[@B6-antibiotics-09-00026]\]. In 2017 the World Health Organization published a list of antibiotic resistant "priority pathogens", a catalogue of bacteria that pose the greatest threat to human health, and clarithromycin resistant *H. pylori* was categorized as a high-priority bacterium \[[@B7-antibiotics-09-00026]\]. Resistance to fluoroquinolones can also impair the efficacy of eradication regimens \[[@B8-antibiotics-09-00026],[@B9-antibiotics-09-00026],[@B10-antibiotics-09-00026]\], whereas resistance to nitroimidazole can be partially overcome in vivo when used in quadruple therapies \[[@B11-antibiotics-09-00026]\]. Antibiotic agents used for *H. pylori* eradication are also widely and improperly used to treat other infections \[[@B7-antibiotics-09-00026],[@B8-antibiotics-09-00026],[@B12-antibiotics-09-00026]\]. For this reason, antibiotic resistance develops continuously, so it is very important to carry out periodic assessments of *H. pylori* primary antibiotic resistance rates and to monitor the efficacy of first line treatments \[[@B13-antibiotics-09-00026],[@B14-antibiotics-09-00026],[@B15-antibiotics-09-00026],[@B16-antibiotics-09-00026]\], thus helping clinicians in selecting the most appropriate therapy in their setting \[[@B17-antibiotics-09-00026]\]. Current Italian guidelines suggest sequential or Pylera^®^ therapy as first line treatments \[[@B8-antibiotics-09-00026],[@B9-antibiotics-09-00026],[@B18-antibiotics-09-00026]\]. Sequential therapy consists of 5 days of a dual therapy with PPI (proton pump inhibitor) and amoxicillin both twice a day followed by 5 days of a triple therapy with PPI, clarithromycin, and metronidazole all twice a day. Pylera^®^ therapy consists of three Pylera^®^ tablets four times a day with PPI twice a day for 10 days. The aim of our study was therefore to evaluate, in Italian naïve *H. pylori* positive patients: (1) resistance rates trends for clarithromycin, metronidazole and levofloxacin over two five-year periods, from 2009 to 2014 vs. 2015 to 2019; (2) which factors are potentially correlated with primary *H. pylori* drug resistance; (3) the effectiveness of sequential therapy.

2. Results {#sec2-antibiotics-09-00026}
==========

A total of 3178 Italian patients were infected, 1646 were naïve with antibiogram available (M/F: 646/1000; median age: 51 years, range 18--85 years). A total of 1763 Italian *H. pylori* positive patients underwent endoscopy between 2009 and 2014, and antibiotic susceptibility test was available in 1551, 907 were naïve; whilst 1415 Italian *H. pylori* positive patients underwent endoscopy between 2015 and 2019, and antibiogram was available in 1132, 739 were naïve ([Figure 1](#antibiotics-09-00026-f001){ref-type="fig"}).

Population features are reported in [Table 1](#antibiotics-09-00026-t001){ref-type="table"}a,b and [Table 2](#antibiotics-09-00026-t002){ref-type="table"}.

Data collected from 2009 to 2014 were compared to data collected from 2015 to 2019 to analyze primary drug resistance trends ([Figure 2](#antibiotics-09-00026-f002){ref-type="fig"}). Antibiotic resistance rates in patients diagnosed in the first and second five-year period were, respectively, clarithromycin 30.2% (95% CI 27.2--33.3) and 37.8% (95% CI 34.2--41.4); metronidazole 33.3% (95% CI 30.2--36.5) and 33.6% (95% CI 30.2--37.1); levofloxacin 25.6% (95% CI 22.8--28.5) and 33.8% (95% IC 30.4--47.4). Double resistance clarithromycin-metronidazole 18.9% (95% CI 16.4--21.6) and 20.7% (95% CI 17.8--23.8) triple resistance clarithromycin-metronidazole-levofloxacin 10.4% (95% CI 8.5--12.5) and 12.6% (95% CI 10.3--15.2).

Total resistance data are shown in [Table 3](#antibiotics-09-00026-t003){ref-type="table"} and [Table 4](#antibiotics-09-00026-t004){ref-type="table"} for 2009--2014 and 2015--2019, respectively.

Although past antibiotic abuse is a key factor for the increase in *H. pylori* antibiotic resistance \[[@B15-antibiotics-09-00026]\], we investigated other factors. Patients diagnosed in the second five-year period (2014--2019) had a higher probability to be clarithromycin and levofloxacin resistant. Female gender was correlated to metronidazole and double (clarithromycin + metronidazole) resistance, with a subsequent high probability of treatment failure. Age was correlated with clarithromycin resistance (younger than 50 years old), levofloxacin and triple resistance (older than 50 years old). Active smokers had higher probability of being resistant to metronidazole.

3. Discussion {#sec3-antibiotics-09-00026}
=============

The treatment of *H. pylori* infection has become complicated by the increasing trend in antimicrobial resistance worldwide \[[@B19-antibiotics-09-00026],[@B20-antibiotics-09-00026]\] primarily because antibiotic agents used for *H. pylori* eradication are also widely used to treat other infections \[[@B7-antibiotics-09-00026],[@B8-antibiotics-09-00026],[@B12-antibiotics-09-00026]\]. Antibiotic resistance develops continuously, so it is very important to carry out periodic assessments of *H. pylori* primary antibiotic resistance rates and to monitor the efficacy of first line treatments \[[@B13-antibiotics-09-00026],[@B14-antibiotics-09-00026],[@B15-antibiotics-09-00026],[@B16-antibiotics-09-00026]\]. Aims of this study were to evaluate the prevalence of primary resistance to clarithromycin, metronidazole, and levofloxacin and to assess the effectiveness of sequential therapy over a 10 years period. The resistance rates to clarithromycin and levofloxacin had both a statistically significant increase (*p* \< 0.05). Despite this, the general eradication rate of the sequential therapy was still optimal, being constantly higher than 90% (PP 93.4%, 95% CI 92--94.6; ITT 87.5%, 95% CI 85.7--89). Only in patients harboring resistant strains to both clarithromycin and metronidazole, the eradication rate was suboptimal (PP 83.6%, 95% CI 78.7--87.5; ITT 77%, 95% CI 71.8--81.5). Nevertheless, it is important to stress that eradication rates had a significant decrease in the second five-year period, going from PP 95.3% (95% CI 93.6--96.5) and ITT 91% (95% CI 88.9--92.7) to PP 90.4% (95% CI 87.6--92.8) and ITT 82.1% (95% CI 78.8--85.1) (*p* \< 0.05). Data of patients of the second five period who took Pylera^®^ therapy have already been published in a previous ad hoc study \[[@B21-antibiotics-09-00026]\]. We investigated the role of factors potentially related with bacterial resistance ([Table 5](#antibiotics-09-00026-t005){ref-type="table"}a,b).

The correlation between the year of *H. pylori* infection diagnosis (2015--2019) with clarithromycin and levofloxacin resistance confirms the significant increase in these antibiotics resistance rates previously observed \[[@B17-antibiotics-09-00026]\]. Isolates collected from women patients are more prone to metronidazole and double clarithromycin/metronidazole resistance; in fact, macrolides and nitroimidazoles are widely used to treat urinary tract infections in women, inducing a selective pressure on *H. pylori* strains \[[@B2-antibiotics-09-00026],[@B22-antibiotics-09-00026]\]. Age was correlated with clarithromycin resistance (younger than 50 years old), levofloxacin, and triple resistance (older than 50 years old) \[[@B22-antibiotics-09-00026]\], this could be due to patients being prescribed more antibiotics (especially fluoroquinolones) \[[@B23-antibiotics-09-00026],[@B24-antibiotics-09-00026]\] at an older age. Smokers had higher probability to be infected by a strain resistant to metronidazole; the correlation between smoke and therapy failure has been described in literature \[[@B25-antibiotics-09-00026],[@B26-antibiotics-09-00026]\], so this observation is very interesting to be further investigated.

4. Materials and Methods {#sec4-antibiotics-09-00026}
========================

4.1. Patients {#sec4dot1-antibiotics-09-00026}
-------------

This was a retrospective, single-center study (Sant'Orsola Hospital, Bologna, Italy) evaluating consecutive Italian patients referred by their physicians to our unit for upper endoscopy. Naïve (never treated for *H. pylori*) *H. pylori* positive patients diagnosed from January 2009 to January 2019 were considered. The exclusion criteria were (1) age 18 years; (2) previous gastric surgery; (3) use of PPI or antibiotics in the 2 weeks before the endoscopy; (4) known allergy to macrolides, nitroimidazoles, or penicillins. Each patient provided us personal information such as age, weight, height, smoking habits, daily intake of alcohol, familiarity for gastric cancer, educational qualifications, and region of birth and residence. All participants provided written informed consent. The study was approved by the local Ethical Committee and performed according to guidelines for Good Clinical Practice \[[@B27-antibiotics-09-00026]\] and the Declaration of Helsinki \[[@B28-antibiotics-09-00026]\].

4.2. Endoscopy and H. pylori Assessment {#sec4dot2-antibiotics-09-00026}
---------------------------------------

Prior to the endoscopy all patients were subjected to ^13^C-urea breath test to detect *H. pylori* infection. The ^13^C-UBT was performed after an overnight fast. A baseline breath sample was obtained, and 75 mg of ^13^C urea with citric acid (1.5 g) was administered as an aqueous solution. Another breath sample was collected 30 min after the test solution was administered. Breath samples were analyzed with non-dispersive infrared spectroscopy (HeliFAN Plus, Fischer Analytic Instruments, Germany). The results of the test were considered as positive if the difference between the baseline sample and the 30-min sample exceeded 4 parts per 1000 of ^13^CO~2~, according to the manufacturer's instructions. During endoscopy biopsy specimens (two from the antrum, two from the corpus, one from incisura angularis) were taken for histology (haematoxylin-eosin for pathological assessment and Giemsa for *H. pylori* staining). One bioptic sample from the antrum was used for rapid urease test (RUT) as routinely performed in our center, and one additional antral biopsy was used for bacterial culture and drug-susceptibility test. *H. pylori* status was assessed through CRM (composite reference method: at least two tests positive or only culture positive). Treatment success was evaluated by using a standard ^13^C-urea breath test performed 6--8 weeks after treatment ended. In the event of an early interruption of eradication therapy, ^13^C-UBT was performed after at least 7 days of treatment. Patients undergoing therapy for fewer than 7 days were considered as drop-outs, and those who did not undergo ^13^C-UBT testing after treatment were considered as lost to follow-up evaluation. Based on endoscopic reports, for the purposes of the study, patients with either a peptic ulcer (ulceration 5 mm in diameter) or mucosal erosions (superficial lesion 4 mm) in the stomach or duodenum were grouped together as "peptic ulcer disease" (PUD). Non-ulcer dyspepsia was diagnosed when no macroscopic lesions were detected at endoscopy and patients were included in "non-ulcer disease" (NUD) group.

4.3. Antibiotics Susceptibility Test for H. pylori {#sec4dot3-antibiotics-09-00026}
--------------------------------------------------

Biopsy specimens collected for bacterial culture were streaked immediately onto commercial selective medium Pylori Agar (BioMérieux Italia S.p.A., Italy). The plates were incubated under microaerobic conditions at 37 °C for 3--5 days. Once incubated, the colonies resembling *H. pylori* were identified by oxidase, catalase, and urease tests. Suspensions from the primary plates were prepared in sterile saline solution to McFarland opacity standard 4, approximately 10^9^ colony forming units (CFU)/mL to perform an E-Test (BioMérieux Italia S.p.A., Italy). A total of three agar plates for every *H. pylori* strain were streaked in three directions with a swab dipped into each bacterial suspension to produce a lawn of growth. Three E-Test strips (clarithromycin 0.016--256 ug/mL, metronidazole 0.016--256 ug/mL, and levofloxacin 0.008--32 ug/mL) were placed each onto a separate plate, which was incubated immediately in a microaerobic atmosphere at 37 °C for 72 h. A fourth plate was used as positive control. Clarithromycin, metronidazole, and levofloxacin resistance break points for the minimal inhibitory concentration (MIC) are greater than 0.5 mg/L, greater than 8 mg/L, and greater than 1 mg/L, respectively, according to the updated recommendations of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@B29-antibiotics-09-00026]\]. From 2015 Eucast established that clarithromycin MICs between \>0.25 and ≤0.5 were to be considered as "indeterminate", suggesting not to administer the drug in this case, so these strains were considered as "resistant" in this study \[[@B30-antibiotics-09-00026]\]. Drug susceptibility test was not performed for amoxicillin and tetracycline because in Europe the resistance rate is lower than 1% \[[@B16-antibiotics-09-00026]\].

4.4. Chemotherapy for H. pylori {#sec4dot4-antibiotics-09-00026}
-------------------------------

According to Italian Guidelines and European Guidelines \[[@B8-antibiotics-09-00026],[@B18-antibiotics-09-00026]\] the first line therapies were sequential or Pylera^®^ therapy. Sequential therapy consist of 5 days of a dual therapy with 40 mg PPI twice a day (before breakfast and dinner) and 1000 mg of amoxicillin twice a day (after breakfast and dinner); followed by 5 days of a triple therapy with 40 mg PPI twice a day (before breakfast and dinner) and clarithromycin 500 mg and metronidazole 500 mg both twice a day (after breakfast and dinner). From 2016 Pylera^®^ was available, a three in one capsule containing 140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline. Pylera^®^ therapy is therefore a 10 days quadruple therapy with 20 mg PPI twice a day (before breakfast and dinner) plus three Pylera^®^ capsules four times a day (after breakfast, lunch, dinner and before bedtime).

4.5. Potential Predictive Factors of Antibiotic Resistance {#sec4dot5-antibiotics-09-00026}
----------------------------------------------------------

Many factors were investigated as potentially correlated to resistance rates. Age (\>50 years or ≤50 years), sex, BMI (\>25 or ≤25), smoking habits (at least one cigarette a day), alcohol consumption (at least one glass a day), familiarity for gastric cancer (first degree relatives), educational level (until middle school or above middle school), City of residence, endoscopic findings (PUD or NUD), and year of *H. pylori* infection diagnosis (2009--2014 vs. 2015--2019).

4.6. Statistical Analysis {#sec4dot6-antibiotics-09-00026}
-------------------------

Means and their 95% confidence intervals were calculated as suggested by Newcombe et al. \[[@B29-antibiotics-09-00026]\]. Eradication rates were calculated both by intention-to-treat (ITT) analysis, including all the enrolled patients, and by per-protocol (PP) analysis, including patients who took more than 90% of their medications and completed follow-up evaluation. Comparisons among patient subgroups were performed using the Chi-square test (Yates correction when appropriate), odd ratio calculator. A *p* level less than 0.05 was considered significant. Statistical analysis was performed with MedCalc19.1.

5. Conclusions {#sec5-antibiotics-09-00026}
==============

The constant increase of resistance rates is a serious problem to be solved. Since virtually all *H. pylori* eradication regimens are based on antimicrobials used also for other infectious diseases, setting up regular monitoring of primary resistance for *H. pylori* (as well as for other microorganisms) should be considered. This would improve the use of appropriate antimicrobial agents and also it would provide an indirect indicator of their use (or abuse) in the population.
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![Population flow chart. Only *Helicobacter pylori* positive naive patients born in Italy were considered.](antibiotics-09-00026-g001){#antibiotics-09-00026-f001}

![*H. pylori* antibiotic resistance rates in 2009--2014 and 2015--2019. (\* Statistically significant). CLA: clarithromycin. Mz: metronidazole. Levo: levofloxacin. R: resistant. RR: resistant to clarithromycin and metronidazole. RRR: resistant to clarithromycin, metronidazole and levofloxacin.](antibiotics-09-00026-g002){#antibiotics-09-00026-f002}

###### 

(**a**) Population features. (**b**) Population features.

antibiotics-09-00026-t001a_Table 1

###### 

 

  \(a\)                                                                        
  ------------------------------------ ------ ------ ------------ ----- ------ ------------
  **Patients**                         907                        739          
  **Male**                             358    39.5   36.3--42.7   288   39.0   35.4--42.6
  **Female**                           549    60.0   57.3--63.7   451   61.0   57.4--64.6
  **Age mean**                         51.5          53                        
  **BMI mean**                         24.3          25                        
  **Smokers**                          205    22.6   19.9--25.5   158   21.4   18.5--24.5
  **Alcohol**                          135    14.9   12.6--17.4   99    13.4   11.0--16.1
  **Cardioaspirin**                    68     7.5    5.9--9.4     56    7.6    5.8--9.7
  **Familiarity for gastric cancer**   118    13.0   10.9--15.4   89    12.0   9.8--14.6
  **Compulsory education**             362    39.0   36.7--43.2   276   37.3   33.8--40.9
  **High school**                      362    39.9   36.7--43.2   311   42.1   38.5--45.7
  **Graduation**                       183    20.2   17.6--22.9   152   20.6   17.7--23.7
  **Chief town**                       397    43.8   40.5--47.1   284   38.4   34.9--42.0
  **Emilia Romagna**                   737    81.3   78.6--83.7   593   80.2   77.2--83.1

95% CI: 95% Confidence Interval. BMI: Body Mass Index.

antibiotics-09-00026-t001b_Table 1

###### 

 

  \(b\)                                              
  ------------------------------------ ------ ------ ------------
  **Patients**                         1646          
  **Male**                             646    39.2   36.9--41.7
  **Female**                           1000   60.8   58.3--63.1
  **Age mean**                         52.3          
  **BMI mean**                         24.6          
  **Smokers**                          363    22.1   20.1--24.1
  **Alcohol**                          234    14.2   12.6--16.0
  **Cardioaspirin**                    124    7.5    6.3--8.9
  **Familiarity for gastric cancer**   207    12.6   11.0--14.3
  **Compulsory education**             638    38.8   36.4--41.2
  **High school**                      673    40.9   38.5--43.3
  **Graduation**                       335    20.4   18.4--22.4
  **Chief town**                       681    41.4   39.0--43.8
  **Emilia Romagna**                   1330   80.8   78.8--82.7

TOT: totals from 2009 to 2019. 95% CI: 95% Confidence Interval. BMI: Body Mass Index.

antibiotics-09-00026-t002_Table 2

###### 

Endoscopic reports.

  UGIE Reports (2009--2019)   No.    \%     95% CI
  --------------------------- ------ ------ ------------
  **NUD**                     1413   85.8   84.0--87.4
  **PUD**                     204    12.3   10.8--14.0
  **MALT lymphoma**           20     1.2    0.7--1.8
  **Gastric cancer**          9      0.5    0.2--1.0

PUD: peptic ulcer (ulceration 5 mm in diameter) or mucosal erosions (superficial lesion 4 mm) in the stomach or duodenum. NUD: no macroscopic lesions detected. MALT: mucosal-associated lymphoid tissue.

antibiotics-09-00026-t003_Table 3

###### 

Primary resistance patterns in *H. pylori* strains collected in 2009--2014.

  907 Naïve          No.   \%     95% CI
  ------------------ ----- ------ ------------
  ClaR, MzR, LevoR   94    10.4   8.5--12.5
  ClaR, MzR, LevoS   77    8.5    6.8--10.5
  ClaR, MzS, LevoR   31    3.4    2.3--4.8
  ClaR, MzS, LevoS   72    7.9    6.3--9.9
  ClaS, MzR, LevoR   46    5.1    3.7--6.7
  ClaS, MzR, LevoS   85    9.4    7.6--11.5
  ClaS, MzS, LevoR   61    6.7    52.0--8.6
  ClaS, MzS, LevoS   441   48.6   45.3--51.9
  Cla R tot          274   30.2   27.2--33.3
  Cla S tot          633   69.8   66.7--72.8
  Mz R tot           302   33.3   30.2--36.5
  Mz S tot           605   66.7   63.5--69.8
  Levo R tot         232   25.6   22.8--28.5
  Levo S tot         675   74.4   71.5--77.2
  ClaR, MzR tot      171   18.9   16.4--21.6

R: resistant. S: susceptible. Cla: clarithromycin. Mz: metronidazole. Levo: levofloxacin.

antibiotics-09-00026-t004_Table 4

###### 

Primary resistance patterns in *H. pylori* strains collected in 2015--2019.

  739 Naive          No.   \%     95% CI
  ------------------ ----- ------ ------------
  ClaR, MzR, LevoR   93    12.6   10.3--15.2
  ClaR, MzR, LevoS   60    8.1    6.3--10.3
  ClaR, MzS, LevoR   46    6.2    4.6--8.2
  ClaR, MzS, LevoS   80    10.8   8.7--13.3
  ClaS, MzR, LevoR   46    6.2    4.6--8.2
  ClaS, MzR, LevoS   49    6.6    4.9--8.7
  ClaS, MzS, LevoR   65    8.8    6.9--11.1
  ClaS, MzS, LevoS   300   40.6   37.0--44.2
  Cla R tot          279   37.8   34.2--41.4
  Cla S tot          460   62.2   58.6--65.8
  Mz R tot           248   33.6   30.2--37.1
  Mz S tot           491   66.4   62.9--69.8
  Levo R tot         250   33.8   30.4--37.4
  Levo S tot         489   66.2   62.6--69.6
  ClaR, MzR tot      153   20.7   17.8--23.8

R: resistant. S: susceptible. Cla: clarithromycin. Mz: metronidazole. Levo: levofloxacin.

###### 

(**a**) Factors potentially correlated with resistance rates. (**b**) Factors potentially correlated with resistance rates.

antibiotics-09-00026-t005a_Table 5

###### 

 

  \(a\)                                    
  --------------------- ------- ---------- ------------
  **2015--2019**        Cla R   1.4        0.001 \*
  Mz R                  1.01    0.910      
  Levo R                1.48    0.000 \*   
  ClaR, MzR             1.23    0.348      
  ClaR, MzR, LevoR      1.24    0.158      
  **Sex female**        Cla R   1.22       0.069
  Mz R                  1.78    0.000 \*   
  Levo R                0.99    0.927      
  ClaR, MzR             1.47    0.003 \*   
  ClaR, MzR, LevoR      1.18    0.309      
  **Age \> 50 years**   Cla R   0.79       0.027 \*\*
  Mz R                  1       0.7054     
  Levo R                1.38    0.003 \*   
  ClaR, MzR             1       0.8291     
  ClaR, MzR, LevoR      1.1     0.003 \*   
  **BMI \> 25**         Cla R   0.9        0.367
  Mz R                  0.9     0.280      
  Levo R                1.06    0.608      
  ClaR, MzR             0.9     0.113      
  ClaR, MzR, LevoR      0.88    0.401      
  **Smokers**           Cla R   1.1        0.447
  Mz R                  1.87    0.000 \*   
  Levo R                1.01    0.927      
  ClaR, MzR             0.97    0.828      
  ClaR, MzR, LevoR      0.96    0.816      

OR: Odd Ratio. BMI: Body Mass Index. \* Statistically significant. \*\* protective.

antibiotics-09-00026-t005b_Table 5

###### 

 

  ------------------------------------------------------------
  \(b\)                                                
  ------------------------------------ ------- ------- -------
  **Daily alcohol consumption**        Cla R   1.01    0.954

  Mz R                                 0.84    0.282   

  Levo R                               1.06    0.701   

  ClaR, MzR                            0.94    0.715   

  ClaR, MzR, LevoR                     1.02    0.725   

  **Familiarity for gastric cancer**   Cla R   0.94    0.689

  Mz R                                 0.95    0.733   

  Levo R                               0.93    0.699   

  ClaR, MzR                            0.94    0.744   

  ClaR, MzR, LevoR                     0.87    0.556   

  **Level of education**\              Cla R   0.86    0.153
  (**till middle school)**                             

  Mz R                                 0.99    0.899   

  Levo R                               1.04    0.724   

  ClaR, MzR                            0.96    0.742   

  ClaR, MzR, LevoR                     1.04    0.809   

  **Residence (main city)**            Cla R   0.92    0.409

  Mz R                                 1       0.637   

  Levo R                               1.08    0.469   

  ClaR, MzR                            0.89    0.375   

  ClaR, MzR, LevoR                     1.04    0.797   

  **PUD**                              Cla R   0.8     0.070

  Mz R                                 0.77    0.120   

  Levo R                               0.85    0.350   

  ClaR, MzR                            0.74    0.157   

  ClaR, MzR, LevoR                     0.78    0.380   
  ------------------------------------------------------------

OR: Odd Ratio. PUD: peptic ulcer disease.
